InterMune Jettisons Actimmune; Picks up $55M for Esbriet Work
By Catherine Shaffer
Wednesday, May 23, 2012
InterMune Inc. agreed to sell its rights to Actimmune (interferon gamma-1b) to Vidara Therapeutics International Ltd. for $55 million in cash plus royalties for two years. InterMune's CEO Dan Welch said divesting Actimmune would free up capital for development and registration of Esbriet (perfenidone) in Europe and other territories, and support other research and development activities.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.